<DOC>
	<DOCNO>NCT00002307</DOCNO>
	<brief_summary>To compare stavudine ( d4T ) zidovudine ( AZT ) slow progression HIV disease . To compare antiviral activity d4T versus AZT measure plasma level p24 antigen HIV viremia , relative efficacy improvement and/or absence adverse change time laboratory parameter associate HIV infection . To compare safety oral dos d4T AZT patient HIV infection .</brief_summary>
	<brief_title>A Comparison Zidovudine ( AZT ) Stavudine HIV-Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Stavudine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : AZT . Patients must : Documented HIV infection determine positive ELISA and/or Western blot . Absolute CD4 count 100 500 cells/mm3 within 90 day prior registration OR CD4 count 50 99 cells/mm3 within 30 day prior registration . Prior zidovudine therapy least 6 month currently tolerate least 500 mg daily . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Newly diagnose AIDSdefining opportunistic infection require acute therapy time enrollment . Need chronic systemic therapy time enrollment . Intractable diarrhea . Signs symptoms bilateral peripheral neuropathy time screen . Demonstrated intolerance zidovudine therapy . Any clinical condition would render patient unsuitable study unable comply dose requirement . Concurrent Medication : Excluded : Chronic systemic therapy agent likely suppress bone marrow , cause neurotoxicity , create hepatic dysfunction . Patients follow prior condition exclude : Prior history bilateral peripheral neuropathy . Demonstrated intolerance zidovudine therapy . Prior Medication : Excluded : Prior d4T , ddI , ddC . Other investigational antiretroviral drug ( e.g. , AZddU , Al 721 , interferon , immunomodulating drug within 1 month prior study entry ribavirin within 3 month prior study entry ) . Prior myelosuppressive , neurotoxic , cytotoxic anticancer therapy within 3 month prior study entry . Any prior therapy would render patient unsuitable study unable comply dose requirement . Required : At least 6 month prior AZT currently tolerate least 500 mg daily , last dose receive 7 day prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Zidovudine</keyword>
	<keyword>Stavudine</keyword>
</DOC>